BioSpace News Archive

Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced an agreement to acquire Synteract, a full-service CRO focused on the rapidly growing emerging biopharma segment. Synteract has built a leading reputation among emerging biopharma, providing deep therapeutic expertise in oncology, rar

Maxar Technologies, a trusted partner and innovator in Earth Intelligence and Space Infrastructure, announced that its Board of Directors declared a regular quarterly dividend of one cent per share.

Conformis, Inc. (NASDAQ:CFMS) announced today that Mark Augusti, President and Chief Executive Officer, and Robert Howe, Chief Financial Officer, will participate in the virtual 2020 Oppenheimer Fall MedTech Summit taking place Thursday, November 12, 2020, in one-on-one meetings. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced the pricing of its underwritten public offering of 4,444,444 shares of its common stock at a price to the public of $90.00 per share resulting in gross proceeds of $400 million, before underwriting discounts.

NCI has announced availability to investigators of oral decitabine and cedazuridine tablets for clinical and nonclinical study proposals under the CRADA The collaboration is intended to study oral decitabine and cedazuridine tablets in a range of tumor types

bioMérieux, a world leader in the field of in-vitro diagnostics, today announced the launch of Predictive Diagnostics – a new offering for food quality and safety programs

The American Heart Association’s 2021 Paul “Bear” Bryant Heart of a Champion Award honors a college football coach for outstanding accomplishments both on and off the field

Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,363,637 shares of common stock of the Company at a price to the public of $2.20 per share, less underwriting discounts and commissions.

The global testosterone replacement therapy market is expected to be influenced by the rising awareness about the diseases itself.

Perfusion systems for solid organ preservation are crucial in transplantation and for preclinical research.